Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Dreyling

Showing results (101-110 of 336) with videos related to

Pageof 34
Sort By:
British Journal of Haematology|October 9, 2014
Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphomaDaniel A Heinrich, Marc Weinkauf, Grit Hutter, et al.
Leukemia & Lymphoma|January 31, 2019
Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshopBrad S Kahl, Martin Dreyling, Leo I Gordon, et al.
Cancer Letters|March 7, 2006
Dendritic cell-based immunogens for B-cell chronic lymphocytic leukemiaThomas Allgeier, Silke Garhammer, Elfriede Nössner, et al.
Leukemia & Lymphoma|February 12, 2014
Recent advances in mantle cell lymphoma: report of the 2013 Mantle Cell Lymphoma Consortium WorkshopLeo I Gordon, Steven H Bernstein, Pedro Jares, et al.
Annals of Hematology|December 15, 2015
Temsirolimus acts as additive with bendamustine in aggressive lymphomaAnna-Katharina Zoellner, Tobias Weiglein, Grit Hutter, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 16, 2022
Inpatient treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): A health economic perspectiveBernhard Moertl, Martin Dreyling, Christian Schmidt, et al.
Annals of Hematology|January 11, 2012
The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphomaGrit Hutter, Malte Rieken, Alessandro Pastore, et al.
Pharmacogenetics and Genomics|August 31, 2010
A multiplex MALDI-TOF MS approach facilitates genotyping of DNA from formalin-fixed paraffin-embedded tumour specimensHeike Horn, Christiane Pott, Jörg Kalla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2005
Treatment strategies in follicular lymphomas: current status and future perspectivesWolfgang Hiddemann, Christian Buske, Martin Dreyling, et al.
British Journal of Haematology|November 18, 2025
A matching-adjusted indirect comparison of survival outcomes with pirtobrutinib (BRUIN) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitorGeorg Heß, Toby A Eyre, Min-Hua Jen, et al.
Pageof 34

Showing results (101-110 of 336) with videos related to

Sort By:
Pageof 34
British Journal of Haematology|October 9, 2014
Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphomaDaniel A Heinrich, Marc Weinkauf, Grit Hutter, et al.
Leukemia & Lymphoma|January 31, 2019
Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshopBrad S Kahl, Martin Dreyling, Leo I Gordon, et al.
Cancer Letters|March 7, 2006
Dendritic cell-based immunogens for B-cell chronic lymphocytic leukemiaThomas Allgeier, Silke Garhammer, Elfriede Nössner, et al.
Leukemia & Lymphoma|February 12, 2014
Recent advances in mantle cell lymphoma: report of the 2013 Mantle Cell Lymphoma Consortium WorkshopLeo I Gordon, Steven H Bernstein, Pedro Jares, et al.
Annals of Hematology|December 15, 2015
Temsirolimus acts as additive with bendamustine in aggressive lymphomaAnna-Katharina Zoellner, Tobias Weiglein, Grit Hutter, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 16, 2022
Inpatient treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): A health economic perspectiveBernhard Moertl, Martin Dreyling, Christian Schmidt, et al.
Annals of Hematology|January 11, 2012
The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphomaGrit Hutter, Malte Rieken, Alessandro Pastore, et al.
Pharmacogenetics and Genomics|August 31, 2010
A multiplex MALDI-TOF MS approach facilitates genotyping of DNA from formalin-fixed paraffin-embedded tumour specimensHeike Horn, Christiane Pott, Jörg Kalla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2005
Treatment strategies in follicular lymphomas: current status and future perspectivesWolfgang Hiddemann, Christian Buske, Martin Dreyling, et al.
British Journal of Haematology|November 18, 2025
A matching-adjusted indirect comparison of survival outcomes with pirtobrutinib (BRUIN) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitorGeorg Heß, Toby A Eyre, Min-Hua Jen, et al.
Pageof 34